Population pharmacokinetics of total and unbound valemetostat and platelet dynamics in healthy volunteers and patients with non‐Hodgkin lymphoma

Documenti analoghi

• Bayesian sparse regression for exposure–response analyses of efficacy and safety endpoints to justify the clinical dose of valemetostat for adult T‐cell leukemia/lymphoma
  di: Masato Fukae, et al.
  Pubblicazione: (2024)
• Population pharmacokinetic modeling of oral brepocitinib in healthy volunteers and patients with immuno‐inflammatory diseases
  di: Farzaneh Maleki, et al.
  Pubblicazione: (2024)
• Population pharmacokinetic analysis of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in patients and healthy volunteers
  di: Eunsol Yang, et al.
  Pubblicazione: (2024)
• Population pharmacokinetic modeling of zavegepant, a calcitonin gene‐related peptide receptor antagonist, in healthy adults and patients with migraine
  di: Craig M. Comisar, et al.
  Pubblicazione: (2024)
• Tipifarnib physiologically‐based pharmacokinetic modeling to assess drug–drug interaction, organ impairment, and biopharmaceutics in healthy subjects and cancer patients
  di: Noriko Okudaira, et al.
  Pubblicazione: (2024)